Apr 13, 2026
Allogene Therapeutics' Off-the-Shelf CAR-T Therapy Eliminates Residual Cancer in B-Cell Lymphoma Patients
Allogene Therapeutics reported new data showing its allogeneic (off-the-shelf) CAR-T treatment successfully eliminated residual cancer cells in B-cell lymphoma patients, potentially offering an easier-to-administer alternative that could delay or prevent cancer recurrence.
1 source
00